Results 1 to 10 of about 2,053,289 (119)

Efficacy of second-line treatment for gemcitabine-refractory unresectable pancreatic cancer in a real-world setting [PDF]

BMC Cancer
Background This study aimed to compare the benefits and identify the best second-line treatment regimen for gemcitabine-refractory unresectable pancreatic cancers.
Qianqian Wang, Nan Lv, Dong Xu, Yang Wu, Junli Wu, Wentao Gao, Jishu Wei, Bin Xiao, Min Tu, Kuirong Jiang   +9 more
doaj   +2 more sources

Clinical audit of current Helicobacter pylori treatment outcomes in Singapore

Singapore Medical Journal, 2022
Introduction: H. pylori eradication reduces the risk of gastric malignancies and peptic ulcer disease. First-line therapies include 14-day PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) and PBMT (PPI, bismuth, metronidazole, tetracycline).
Tiing Leong Ang, Kim Wei Lim, Daphne Ang, Yu Jun Wong, Malcolm Tan, Andrew Siang Yih Wong   +5 more
doaj   +1 more source

Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study

Frontiers in Oncology, 2022
AimsThis study aimed to observe the efficacy and safety of anlotinib in the treatment of small cell lung cancer (SCLC) in the real world, as first-line maintenance therapy, second-line, and above.MethodsClinical data of 109 patients with SCLC treated ...
Jing Yuan, Feng Cheng, Guodong Xiao, Xiaofeng Wang, Huijie Fan   +4 more
doaj   +1 more source

Second-line treatment options in hepatocellular carcinoma

Drugs in Context, 2019
For many years, sorafenib has been the only approved systemic treatment for advanced hepatocellular carcinoma (HCC). For over a decade, randomized controlled trials exploring the efficacy of new drugs both in first- and second-line treatment have failed ...
Donatella Marino, Clizia Zichi, Marco Audisio, Elisa Sperti, Massimo Di Maio   +4 more
doaj   +1 more source

A case of effective disease control of advanced gastric cancer following ramucirumab plus FOLFIRI in second line treatment in clinical practice

Медицинский совет, 2020
Ramucirumab is a human anti-vascular endothelial growth factor receptor 2(VEGFR-2)monoclonal antibodythat acts on vascular endothelial cells to inhibit angiogenesis.
T. A. Titova, N. S. Besova, E. A. Artamonova   +2 more
doaj   +1 more source

Chemotherapy in Pancreatic Cancer: A Systematic Review

Medicina, 2018
Background and Aim: Pancreatic cancer is one of the most fatal cancers. Cytotoxic chemotherapy remains the mainstream treatment for unresectable pancreatic cancer.
Leva Hajatdoost, Keyvan Sedaghat, Erin J. Walker, Jackson Thomas, Sam Kosari   +4 more
doaj   +1 more source

Tolerance of ramucirumab in the second-line therapy of patients with disseminated gastric cancer in the routine clinical practice of Russia

Медицинский совет, 2019
Introduction: Ramucirumab (Ram), a human IgG 1 antibody against vascular endothelial growth factor receptor 2. This multicenter retrospective study aims to reviewed the results of Ram-based therapy as second-line treatment in patients with advanced ...
N. S. Besova, T. A. Titova, E. V. Artamonova, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukal’chuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, A. A. Tryakin, I. S. Stilidi   +19 more
doaj   +1 more source

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report

Frontiers in Oncology, 2023
Hepatocellular carcinoma (HCC) is a tumor with a high degree of malignancy. Patients have poor outcomes and short survival times, especially after progression to first-line systemic therapy.
Yanzhi Wan, Hong Zhu
doaj   +1 more source

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer

Медицинский совет, 2019
Background: Several studies show that the combination chemotherapy with ramucirumab allows to improve the treatment results of advanced gastric cancer (GC).
N. S. Besova, T. A. Titova, D. L. Stroyakovsky, E. V. Perminova, S. G. Bagrova, E. S. Obarevich, V. A. Gorbunova, E. V. Artamonova, I. S. Stilidi   +8 more
doaj   +1 more source

Results of the use of ramucirumab in combination with paclitaxel or ramucirumab monotherapy as the second line treatment in patients with disseminated HER2-negative gastric or cardioesophageal junction adenocarcinoma: experience of N.N. Blokhin russian cancer research center of the ministry of health of Russia

Медицинский совет, 2018
Background. Working out of the second line chemotherapy of advanced gastric adenocarcinoma is a promising approach to cancer therapy. Ramucirumab, an anti-angiogenic agent specifically targeting vascular endothelial growth factor receptor-2 (VEGFR-2). In
N. S. Besova, T. A. Titova, E. V. Trusilova, V. A. Gorbunova, A. A. Tryakin, O. O. Gordeeva, A. A. Rumyantsev, R. Yu. Nasyrova, L. G. Zhukova, A. V. Snegovoy, E. V. Artamonova, L. V. Manzyuk, A. A. Fedenko   +12 more
doaj   +1 more source